Oncopeptides develops Melflufen, intended for the treatment of multiple myeloma. Multiple myeloma is currently an incurable blood-related cancer with median survival of 7 years. Melflufen kills cancer cells more effectively than current drugs in the same class (so-called alkylators). Oncopeptides is a public company listed on NASDAQ Stockholm.
General
| General |
|---|
| Exit date: February 2021 |
| Country HQ: Sweden |
| Industry: Cancer treatment |
| Web page: www.oncopeptides.com |